Cardio Diagnostics Holdings (CDIO) Amortizatization of Intangibles (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Amortizatization of Intangibles of $50412.0 for Q1 2026, up 1.11% sequentially from $49857.0 in Q4 2025, and down 42.49% YoY from $87664.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Amortizatization of Intangibles for 5 years, with the latest figure at $50412.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 42.49% year-over-year to $50412.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113076.0 (down 16.98% YoY) and the FY2025 annual result came in at $238065.0, up 46.44% from the prior year.
- Amortizatization of Intangibles climbed to $50412.0 in Q1 2026 per CDIO's latest filing, from $49857.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $87664.0 in Q1 2025 and troughed at $794.0 in Q2 2024.
- A 5-year average of $23403.1 and a median of $5655.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles soared 1385.1% in 2023, then tumbled 97.94% in 2024.
- Over 5 years, Amortizatization of Intangibles stood at $4000.0 in 2022, then jumped by 1385.1% to $59404.0 in 2023, then slipped by 20.99% to $46936.0 in 2024, then grew by 6.22% to $49857.0 in 2025, then climbed by 1.11% to $50412.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $50412.0, $49857.0, and $5655.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cardio Diagnostics Holdings | 6.05 Mn | 460,682.10 | - | 5,593.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5,593.00 |
| Jun 30, 2026 | 5,593.00 |
| Mar 31, 2026 | 50,412.00 |
| Mar 31, 2026 | 50,412.00 |
| Dec 31, 2025 | 49,857.00 |
| Dec 31, 2025 | 49,857.00 |
| Sep 30, 2025 | 5,655.00 |
| Sep 30, 2025 | 5,655.00 |
| Jun 30, 2025 | 7,152.00 |
| Jun 30, 2025 | 7,152.00 |
| Mar 31, 2025 | 87,664.00 |
| Mar 31, 2025 | 87,664.00 |
| Dec 31, 2024 | 46,936.00 |
| Dec 31, 2024 | 46,936.00 |
| Sep 30, 2024 | 802.00 |
| Sep 30, 2024 | 802.00 |
| Jun 30, 2024 | 794.00 |
| Jun 30, 2024 | 794.00 |
| Mar 31, 2024 | 24,750.00 |
| Mar 31, 2024 | 24,750.00 |